John Houston
President & CEO
protein degradationdrug developmentbiotech strategy
Details
- ●Modalities: PROTACs (targeted protein degradation), small molecules
- ●Therapeutic areas: oncology, neuroscience
- ●Key targets: estrogen receptor, androgen receptor, LRRK2, tau, BCL6
- ●Indications: ER+/HER2- breast cancer, metastatic castration-resistant prostate cancer, Parkinson's disease (LRRK2), Alzheimer's disease (tau)
- ●Funding: $685M cash on hand (end 2025)
Partners & investors
- Public (NASDAQ: ARVN)· Investor
- Pfizer (50/50 development partner)· Investor
Key considerations
- ●AI tools in use: PROTAC design platform (ternary complex modeling), Computational E3 ligase-target pair prediction, Structure-based degrader design
- ●Pioneered PROTAC technology with computational ternary complex modeling
- ●50/50 partnership with Pfizer on vepdegestrant (shared development costs)
- ●$685M cash (end 2025), runway to H2 2028
Pipeline
- Preclinical1
- Phase 11
- Phase 31
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Craig Crews
Founder & Chief Scientific Advisor
PROTAC inventionchemical biologytargeted protein degradation